Avid Bioservices Inc (CDMO)

[Charlie Stein]

"Expected survival for patients with GBM is approximately six months from the time of disease recurrence."

That's right, and yet with Cotara, "All Patients in the First Two Cohorts Have Met or Exceeded the Expected Median Survival Time for Recurrent GBM Patients." That either means that some patients died at the six month mark (but none earlier), or else that all patients lived past the six month mark.

Now, "[t]he main objectives of the open label dosing and dosimetry study are to confirm the maximum tolerated dose of Cotara, to determine radiation dosimetry and to assess overall patient survival, progression free survival and the proportion of patients alive at six months following Cotara administration."

I would think that "the proportion of patients alive at six months following Cotara administration" would therefore be 100% (unless some died right at the six month mark)?

I think that someone needs to wake up and get this into the hands of doctors treating GBM patients.